A phase IIa, double-blind, randomized, parallel-design, four-week study to investigate the efficacy and safety of two different doses of the renin-inhibitor SPP635 once daily in type II diabetic patients with mild to moderate hypertension and albuminuria [proteinuria].
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2012
At a glance
- Drugs SPP 635 (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 16 Mar 2012 Additional location (Hungary) added as reported by European Clinical Trials Database record.
- 20 Nov 2008 Status changed from active, no longer recruiting to completed.
- 15 Sep 2008 Checked against NCT00561171.